ADMA Capital Expenditures vs Begin Period Cash Flow Analysis

ADMA Stock

USD 17.72 1.26 6.64%

ADMA Biologics financial indicator trend analysis is way more than just evaluating ADMA Biologics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ADMA Biologics is a good investment. Please check the relationship between ADMA Biologics Capital Expenditures and its Begin Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.

Capital Expenditures vs Begin Period Cash Flow

Capital Expenditures vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ADMA Biologics Capital Expenditures account and Begin Period Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between ADMA Biologics' Capital Expenditures and Begin Period Cash Flow is 0.44. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of ADMA Biologics, assuming nothing else is changed. The correlation between historical values of ADMA Biologics' Capital Expenditures and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of ADMA Biologics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Capital Expenditures i.e., ADMA Biologics' Capital Expenditures and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.44

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by ADMA Biologics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of ADMA Biologics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from ADMA Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ADMA Biologics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.At present, ADMA Biologics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 226.09, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	79.8M	118.8M	169.3M	177.7M
Research Development	3.6M	3.6M	3.3M	4.4M

Cost Of Revenue Research Development

ADMA Biologics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Net Debt	Cash	Common Stock Shares Outstanding	Total Liab	Total Current Assets	Other Current Liab	Total Stockholder Equity	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Other Stockholder Equity	Common Stock	Retained Earnings	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Other Assets	Net Receivables	Inventory	Other Current Assets	Property Plant And Equipment Gross	Non Currrent Assets Other	Other Liab
Total Assets		0.98	0.95	0.91	0.81	0.98	0.99	1.0	0.9	0.98	0.8	-0.11	0.98	0.99	-0.09	-0.98	0.98	0.98	0.96	0.3	0.93	0.98	0.85	0.96	0.54	0.16
Short Long Term Debt Total	0.98		0.94	0.95	0.79	0.96	0.99	0.98	0.88	0.94	0.78	-0.12	0.99	0.98	-0.1	-0.98	0.98	0.98	0.95	0.3	0.88	0.97	0.86	0.95	0.56	0.19
Total Current Liabilities	0.95	0.94		0.92	0.65	0.99	0.96	0.96	0.98	0.92	0.65	0.01	0.93	0.95	0.04	-0.93	0.91	0.94	0.87	0.05	0.92	0.98	0.72	0.95	0.5	0.04
Net Debt	0.91	0.95	0.92		0.58	0.93	0.95	0.91	0.88	0.84	0.57	-0.13	0.94	0.93	-0.1	-0.94	0.9	0.94	0.88	0.15	0.86	0.94	0.72	0.93	0.52	0.11
Cash	0.81	0.79	0.65	0.58		0.69	0.78	0.79	0.57	0.82	1.0	-0.09	0.8	0.78	-0.08	-0.78	0.82	0.75	0.81	0.56	0.63	0.73	0.95	0.66	0.47	0.31
Common Stock Shares Outstanding	0.98	0.96	0.99	0.93	0.69		0.97	0.98	0.96	0.95	0.69	-0.09	0.95	0.97	-0.06	-0.95	0.94	0.95	0.9	0.12	0.93	0.99	0.77	0.96	0.48	0.05
Total Liab	0.99	0.99	0.96	0.95	0.78	0.97		0.98	0.89	0.94	0.77	-0.12	1.0	0.99	-0.09	-0.99	0.98	0.99	0.96	0.3	0.89	0.97	0.84	0.97	0.58	0.15
Total Current Assets	1.0	0.98	0.96	0.91	0.79	0.98	0.98		0.92	0.98	0.79	-0.1	0.97	0.99	-0.07	-0.97	0.96	0.97	0.93	0.22	0.93	0.99	0.84	0.94	0.5	0.15
Other Current Liab	0.9	0.88	0.98	0.88	0.57	0.96	0.89	0.92		0.88	0.57	0.13	0.86	0.88	0.16	-0.86	0.83	0.86	0.78	-0.1	0.88	0.95	0.65	0.9	0.42	-0.04
Total Stockholder Equity	0.98	0.94	0.92	0.84	0.82	0.95	0.94	0.98	0.88		0.81	-0.09	0.93	0.97	-0.07	-0.94	0.95	0.94	0.92	0.27	0.94	0.97	0.84	0.91	0.47	0.16
Cash And Short Term Investments	0.8	0.78	0.65	0.57	1.0	0.69	0.77	0.79	0.57	0.81		-0.11	0.79	0.78	-0.11	-0.78	0.8	0.74	0.79	0.54	0.62	0.72	0.94	0.65	0.48	0.3
Common Stock Total Equity	-0.11	-0.12	0.01	-0.13	-0.09	-0.09	-0.12	-0.1	0.13	-0.09	-0.11		-0.13	-0.17	1.0	0.19	-0.14	-0.17	-0.15	-0.33	-0.16	-0.08	-0.11	-0.12	-0.01	-0.06
Non Current Liabilities Total	0.98	0.99	0.93	0.94	0.8	0.95	1.0	0.97	0.86	0.93	0.79	-0.13		0.98	-0.11	-0.98	0.99	0.98	0.97	0.36	0.87	0.96	0.86	0.96	0.59	0.18
Other Stockholder Equity	0.99	0.98	0.95	0.93	0.78	0.97	0.99	0.99	0.88	0.97	0.78	-0.17	0.98		-0.14	-1.0	0.98	0.99	0.96	0.31	0.93	0.98	0.83	0.96	0.55	0.18
Common Stock	-0.09	-0.1	0.04	-0.1	-0.08	-0.06	-0.09	-0.07	0.16	-0.07	-0.11	1.0	-0.11	-0.14		0.17	-0.12	-0.14	-0.13	-0.34	-0.13	-0.05	-0.1	-0.09	0.0	-0.07
Retained Earnings	-0.98	-0.98	-0.93	-0.94	-0.78	-0.95	-0.99	-0.97	-0.86	-0.94	-0.78	0.19	-0.98	-1.0	0.17		-0.98	-0.99	-0.96	-0.34	-0.91	-0.96	-0.84	-0.95	-0.56	-0.19
Property Plant And Equipment Net	0.98	0.98	0.91	0.9	0.82	0.94	0.98	0.96	0.83	0.95	0.8	-0.14	0.99	0.98	-0.12	-0.98		0.98	0.99	0.44	0.89	0.94	0.86	0.95	0.61	0.19
Accounts Payable	0.98	0.98	0.94	0.94	0.75	0.95	0.99	0.97	0.86	0.94	0.74	-0.17	0.98	0.99	-0.14	-0.99	0.98		0.96	0.32	0.92	0.96	0.8	0.97	0.58	0.21
Non Current Assets Total	0.96	0.95	0.87	0.88	0.81	0.9	0.96	0.93	0.78	0.92	0.79	-0.15	0.97	0.96	-0.13	-0.96	0.99	0.96		0.52	0.86	0.9	0.84	0.94	0.64	0.19
Other Assets	0.3	0.3	0.05	0.15	0.56	0.12	0.3	0.22	-0.1	0.27	0.54	-0.33	0.36	0.31	-0.34	-0.34	0.44	0.32	0.52		0.14	0.14	0.51	0.25	0.45	0.42
Net Receivables	0.93	0.88	0.92	0.86	0.63	0.93	0.89	0.93	0.88	0.94	0.62	-0.16	0.87	0.93	-0.13	-0.91	0.89	0.92	0.86	0.14		0.94	0.66	0.92	0.44	0.12
Inventory	0.98	0.97	0.98	0.94	0.73	0.99	0.97	0.99	0.95	0.97	0.72	-0.08	0.96	0.98	-0.05	-0.96	0.94	0.96	0.9	0.14	0.94		0.8	0.95	0.47	0.1
Other Current Assets	0.85	0.86	0.72	0.72	0.95	0.77	0.84	0.84	0.65	0.84	0.94	-0.11	0.86	0.83	-0.1	-0.84	0.86	0.8	0.84	0.51	0.66	0.8		0.72	0.46	0.34
Property Plant And Equipment Gross	0.96	0.95	0.95	0.93	0.66	0.96	0.97	0.94	0.9	0.91	0.65	-0.12	0.96	0.96	-0.09	-0.95	0.95	0.97	0.94	0.25	0.92	0.95	0.72		0.57	0.14
Non Currrent Assets Other	0.54	0.56	0.5	0.52	0.47	0.48	0.58	0.5	0.42	0.47	0.48	-0.01	0.59	0.55	0.0	-0.56	0.61	0.58	0.64	0.45	0.44	0.47	0.46	0.57		0.03
Other Liab	0.16	0.19	0.04	0.11	0.31	0.05	0.15	0.15	-0.04	0.16	0.3	-0.06	0.18	0.18	-0.07	-0.19	0.19	0.21	0.19	0.42	0.12	0.1	0.34	0.14	0.03

Click cells to compare fundamentals

ADMA Biologics Account Relationship Matchups

ADMA Biologics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	127.1M	207.7M	276.3M	348.5M	329.2M	345.6M
Short Long Term Debt Total	84.7M	97.7M	102.9M	154.4M	141.4M	148.5M
Total Current Liabilities	14.0M	19.9M	30.4M	39.3M	49.8M	52.3M
Net Debt	58.0M	41.7M	51.8M	67.9M	90.1M	94.6M
Cash	26.8M	55.9M	51.1M	86.5M	51.4M	27.8M
Common Stock Shares Outstanding	54.3M	86.1M	139.6M	197.9M	224.0M	235.2M
Liabilities And Stockholders Equity	127.1M	207.7M	276.3M	348.5M	329.2M	345.6M
Total Liab	100.9M	119.4M	135.1M	196.5M	194.0M	203.7M
Total Current Assets	85.8M	153.7M	208.7M	270.4M	257.0M	269.9M
Other Current Liab	4.5M	8.0M	17.2M	25.1M	32.9M	34.6M
Total Stockholder Equity	26.2M	88.2M	141.2M	152.0M	135.2M	142.0M
Cash And Short Term Investments	26.8M	55.9M	51.1M	86.5M	51.4M	29.7M
Common Stock Total Equity	5.9K	10.5K	19.6K	22.2K	20.0K	19.0K
Non Current Liabilities Total	86.9M	99.5M	104.7M	157.2M	144.2M	151.4M
Other Stockholder Equity	290.9M	428.7M	553.3M	630.0M	641.4M	673.5M
Common Stock	5.9K	10.5K	19.6K	22.2K	23K	29.8K
Retained Earnings	(264.7M)	(340.5M)	(412.1M)	(478.0M)	(506.3M)	(480.9M)
Property Plant And Equipment Net	31.7M	45.9M	58.2M	68.7M	63.5M	66.6M
Accounts Payable	9.2M	11.1M	12.4M	13.2M	15.7M	16.4M
Non Current Assets Total	41.3M	53.9M	67.5M	78.1M	72.2M	75.8M
Other Assets	2.8M	6.4M	4.1M	4.8M	1.0	0.95
Net Receivables	3.5M	13.2M	28.6M	15.5M	27.4M	28.8M
Inventory	53.1M	81.5M	124.7M	163.3M	172.9M	181.6M
Other Current Assets	2.5M	6.1M	4.3M	10.2M	5.3M	2.8M
Property Plant And Equipment Gross	31.7M	45.9M	50.9M	58.3M	90.2M	94.7M
Non Currrent Assets Other	2.8M	2.1M	4.1M	4.8M	4.7M	4.9M
Other Liab	2.4M	2.2B	2.4M	3.7M	4.2M	4.0M
Net Tangible Assets	19.5M	82.3B	141.2M	152.0M	174.8M	166.0M
Long Term Debt	68.3M	93.0M	94.9M	142.8M	130.6M	137.1M
Retained Earnings Total Equity	(264.7M)	(340.5M)	(412.1M)	(478.0M)	(430.2M)	(408.7M)
Capital Surpluse	290.9M	428.7M	553.3M	630.0M	724.5M	760.7M
Capital Lease Obligations	1.3M	4.7M	8.1M	11.6M	10.8M	11.4M
Non Current Liabilities Other	15.0M	54.9K	397.4K	1.9M	2.1M	2.0M
Short Term Debt	229.1K	731.4K	591.1K	905K	863.0K	1.2M
Intangible Assets	3.2M	2.4M	1.7M	1.0M	499K	474.1K
Property Plant Equipment	31.7M	45.9B	50.9M	58.3M	67.0M	63.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:

How To Invest In ADMA

Details

Is ADMA Stock a good investment?

Details

What is ADMA Biologics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

Earnings Share

0.27

Revenue Per Share

1.661

Quarterly Revenue Growth

0.781

Return On Assets

0.1989

The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ADMA Capital Expenditures vs Begin Period Cash Flow Analysis

Capital Expenditures vs Begin Period Cash Flow

Capital Expenditures vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Capital Expenditures

Begin Period Cash Flow

ADMA Biologics fundamental ratios Correlations

ADMA Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ADMA Biologics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Non Current Liabilities Total	+ 1.0	Total Liab
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 0.99	Total Assets
Other Stockholder Equity	+ 0.99	Total Assets

Retained Earnings	- 1.0	Other Stockholder Equity
Accounts Payable	- 0.99	Retained Earnings
Retained Earnings	- 0.99	Total Liab
Property Plant And Equipment Net	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Non Current Liabilities Total
Retained Earnings	- 0.98	Short Long Term Debt Total